O ovoj e-knjizi
Features:
- Discusses scientific solutions and process analytical technology to enable continuous manufacturing in the development of new drugs
- Includes short stories about how some companies have adopted CM and what their drivers were and what benefits were realized
- Addresses economic and practical considerations, unlike many other technical books
- Emphasizes the practical aspects to give the reader the strategic imperative and technological depth to adopt and implement these technologies
- Highlights the "why" and the "how", focusing on the need analysis and process modeling and process analytical technologies
O autoru
Dr. Ajit Narang
Ajit Narang works for the Small Molecule Pharmaceutical Sciences Department of Genentech, Inc., in South San Francisco, CA responsible for the pharmaceutical development of new chemical entities through preclinical and early clinical stages.
He holds about two decades of pharmaceutical industry experience in the development and commercialization of oral and parenteral dosage forms and drug delivery platforms across preclinical through commercialization stages for both small and large molecule drugs. In addition to Genentech, he has worked for Bristol-Myers Squibb, Co., in New Brunswick, NJ; Ranbaxy Research Labs (currently a subsidiary of Daiichi Sankyo, Japan) in Gurgaon, India; and Morton Grove Pharmaceuticals (currently, Wockhardt USA) in Gurnee, IL. He holds undergraduate Pharmacy degree from the University of Delhi, India and graduate degrees in Pharmaceutics from the Banaras Hindu University, India and the University of Tennessee Health Science Center (UTHSC) in Memphis, TN.
Dr. Ajit has contributed to several preclinical, clinical, and commercialized drug products including NDAs, ANDAs, and 505B2s. He is credited with 54 peer-reviewed articles; 22 editorial contributions; 5 books; 10 patent applications; 47 invited talks; and 85 presentations at various scientific meetings. His current research interests are translation from preclinical to clinical and commercial drug product design; incorporation of QbD elements in drug product development; and mechanistic understanding of the role of material properties on product performance.
Dr. Atul Dubey
Atul Dubey is the Director of Pharmaceutical Continuous Manufacturing (PCM) at the United States Pharmacopeial Convention (USP). Headquartered in Rockville, MD, USA, USP is committed to global public health and quality of medicines for 200 years.
At USP, his group is focused on supporting the ongoing adoption of CM through education programs, public standards and collaborative work for standardization and harmonization. Atul is involved in the development of training curriculum for industry personnel to bring about technological awareness about CM. He is also a part of the expert working group (EWG) for drafting the ICH Q13 guideline for CM. He collaborates with various stakeholders to carry out scientific research in various aspects of CM.
After earning his PhD degree in Mechanical Engineering, he carried out research in pharmaceutical manufacturing processes using modeling and simulation to understand and optimize unit operations such as continuous mixing, granulation and pan coating. He has authored several journal articles and book chapters in the domain.
After his stint at the C-SOPS (Rutgers University) he moved to India where he worked as a consultant to pharmaceutical companies, as well as a Sr. Scientist in the Aditya Birla Group in India. With a strong motivation to facilitate the access to quality medicines worldwide, he is interested in applied R&D towards development of new standards, training and guidelines for CM.
